Regencell Bioscience Holdings Limited

US$5.27As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:RGCHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR 79.46%
Div yield —
ROE (128.52%)
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 1.71
PE TTM —
TSR TTM (68.35%)
Mkt cap US$2.613B
ROIC (76.93%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$5.13
(2.64%)
(16.39%)
Hold 2|3|9|9|5
2Q26
3Q26
4Q26
1Q27
Earnings per share$
0.06
0.06
0.06
0.07
3.57%
5.49%
4.58%
16.58%
Revenue$M
352.0
356.8
375.0
372.7
9.31%
11.53%
12.31%
6.45%
Peers (US$2.613B)
Cap (US$)
PE
2.573B
144.6x
Capital
TTM
5Y
10Y
Leveragex
2.871
0.204
0.195
EBIT/Intx
0.996
0.303
0.284
Own earn%
(160.80)
(137.01)
(107.86)
Sh yield%
45.77
40.58
38.43
Owners
Insiders/Inst%
9.75
59.17
Short interest%
1.64
SBC / revenue%
3.34
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
5
Op margin range%
23–28
$1 testx
—
Incr. ROIC%
0